Materials & Resources » Chemicals | Cambrex Corp.

Cambrex Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
25,915.00
57,303.00
57,217.00
81,678.00
102,450.00
92,418
Depreciation, Depletion & Amortization
22,473.00
23,826.00
22,061.00
24,665.00
31,848.00
37,857
Other Funds
301.00
522.00
1,445.00
10,278.00
-
6,558
Funds from Operations
57,809.00
68,854.00
109,256.00
105,510.00
151,388.00
121,660
Changes in Working Capital
20,935.00
3,886.00
25,650.00
17,768.00
2,373.00
34,678
Net Operating Cash Flow
36,874.00
64,968.00
83,606.00
123,278.00
149,015.00
86,982
Capital Expenditures
57,320.00
23,323.00
62,491.00
49,714.00
52,143.00
Sale of Fixed Assets & Businesses
2,378.00
2,355.00
2,308.00
13.00
2,836.00
Purchase/Sale of Investments
1,655.00
1,404.00
-
-
-
Net Investing Cash Flow
56,597.00
24,798.00
60,239.00
73,976.00
49,307.00
Issuance/Reduction of Debt, Net
15,250.00
19,250.00
30,000.00
32,515.00
-
Net Financing Cash Flow
18,173.00
14,525.00
22,739.00
17,296.00
4,781.00
Net Change in Cash
806.00
22,773.00
1,544.00
30,167.00
109,143.00
Free Cash Flow
20,446.00
41,645.00
21,115.00
73,564.00
96,872.00
Deferred Taxes & Investment Tax Credit
5,902.00
16,025.00
19,736.00
8,556.00
6,925.00
2,057
Net Assets from Acquisitions
-
2,426.00
-
24,275.00
-
Change in Capital Stock
3,224.00
4,203.00
5,816.00
4,941.00
4,781.00
Exchange Rate Effect
744.00
2,872.00
2,172.00
1,839.00
4,654.00
Other Uses
-
-
56.00
-
-

About Cambrex

View Profile
Address
One Meadowlands Plaza
East Rutherford New Jersey 07073
United States
Employees -
Website http://www.cambrex.com
Updated 07/08/2019
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.